Asthma Clinical Trial
Official title:
Social Support and Education in Asthma Follow-up (SSEA)
We will evaluate the effect of an eighteen-month asthma coaching intervention for
parents/caregivers of children with asthma to reduce asthma morbidity. The primary objective
is to determine if asthma coaching will significantly reduce asthma morbidity as measured by
a reduction in the number of ED visits and hospitalizations for the children during the 18
months of active coaching and during the 18 months after the coaching stops.
We will provide half of the subjects (parents/caregivers) with access to assistance from an
asthma coach for 18 months (including 2 contacts with an asthma nurse during the first 6
months). The other half of the subjects will not have an asthma coach, but their children
will have their usual routine care with their primary care providers. The nurse and coach
will help the subjects learn more about caring for their children's asthma and improving
interactions with the primary care providers for their children.
BACKGROUND:
Our previous NHLBI-supported study (HL 57232) showed that a combination treatment of
"Coaching" through follow-up phone calls 2 and 5 days following an index ED visit plus
monetary incentive was highly effective in increasing the percentage of low-income urban
children who received recommended primary care within 2 weeks of the ED visit for asthma, 44%
in the intervention group vs 29% in usual care (p = 0.0004). However, the intervention was
not associated with significant differences in morbidity (subsequent ED visits). We conclude
that the intervention was effective in promoting the initial link to primary care, but was
not effective in sustaining that link or management practices to minimize acuity of symptoms
during exacerbation.
DESIGN NARRATIVE:
Primary outcome The proportion of children of subjects in each group who have at least one ED
visit for acute asthma symptoms during the thirty-six month period following enrollment.
Key secondary outcomes A. The proportion of children of subjects in each group who are
hospitalized during the thirty-six month period following enrollment.
B. The proportion of children of subjects in each group who have either acute asthma visits
or asthma-planning visits with their primary care providers.
C. The costs of asthma-related care during the thirty-six month period D. Variables which may
mediate or moderate the intervention such as the attitudes toward asthma care of the subjects
and the personal social support perceived by the subjects .
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|